Lilly’s Taltz (ixekizumab) Receives Health Canada’s Approval for Pediatric Patients with Moderate to Severe Plaque Psoriasis

April 5, 2021 Auto Bot approval, Health Canada, Lilly, Moderate, patients, Pediatric, Plaque Psoriasis, receives, regulatory, Severe 0

Shots:

  • The approval is based on P-III study involves assessing Taltz (20mg for <25kg/40mg for 25-50kg/80 mg for >50 kg @12wks., with 40/80/160mg starting doses, respectively) vs PBO in 171 patients aged 6-<18 yrs. with mod. to sev. PsO
  • Results: @ 12wks., patients achieving PASI 75 (89% vs 25%); patients achieving sPGA 0,1 (81% vs 11%); safety profile in pediatric patients is consistent with adult patients
  • Taltz is a mAb targeting IL-17A cytokine. The approval marks the 5th indication for the therapy in Canada and has received its first approval in 2016 for mod. to sev. PsO, then for PsA in 2018, AS & nr-axSpA in 2020

Click here to­ read full press release/ article | Ref: Lilly | Image: Fortune

The post Lilly’s Taltz (ixekizumab) Receives Health Canada’s Approval for Pediatric Patients with Moderate to Severe Plaque Psoriasis first appeared on PharmaShots.